TISIDB

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane; Single-pass type I membrane protein.
Domain	PF00020 TNFR/NGFR cysteine-rich region
Function	Receptor for CD70/CD27L. May play a role in survival of activated T-cells. May play a role in apoptosis through association with SIVA1.

> Gene Ontology [ TOP ]
Biological Process	GO:0002237 response to molecule of bacterial origin GO:0002250 adaptive immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0006606 protein import into nucleus GO:0006913 nucleocytoplasmic transport GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0007253 cytoplasmic sequestering of NF-kappaB GO:0007254 JNK cascade GO:0008588 release of cytoplasmic sequestered NF-kappaB GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors GO:0010466 negative regulation of peptidase activity GO:0010951 negative regulation of endopeptidase activity GO:0016064 immunoglobulin mediated immune response GO:0017038 protein import GO:0019724 B cell mediated immunity GO:0030098 lymphocyte differentiation GO:0030183 B cell differentiation GO:0031098 stress-activated protein kinase signaling cascade GO:0031503 protein complex localization GO:0032386 regulation of intracellular transport GO:0032387 negative regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0032496 response to lipopolysaccharide GO:0032507 maintenance of protein location in cell GO:0032872 regulation of stress-activated MAPK cascade GO:0032874 positive regulation of stress-activated MAPK cascade GO:0033157 regulation of intracellular protein transport GO:0033209 tumor necrosis factor-mediated signaling pathway GO:0034504 protein localization to nucleus GO:0034612 response to tumor necrosis factor GO:0042113 B cell activation GO:0042306 regulation of protein import into nucleus GO:0042307 positive regulation of protein import into nucleus GO:0042308 negative regulation of protein import into nucleus GO:0042345 regulation of NF-kappaB import into nucleus GO:0042346 positive regulation of NF-kappaB import into nucleus GO:0042347 negative regulation of NF-kappaB import into nucleus GO:0042348 NF-kappaB import into nucleus GO:0042990 regulation of transcription factor import into nucleus GO:0042991 transcription factor import into nucleus GO:0042992 negative regulation of transcription factor import into nucleus GO:0042993 positive regulation of transcription factor import into nucleus GO:0042994 cytoplasmic sequestering of transcription factor GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043410 positive regulation of MAPK cascade GO:0044744 protein targeting to nucleus GO:0045185 maintenance of protein location GO:0045471 response to ethanol GO:0045577 regulation of B cell differentiation GO:0045579 positive regulation of B cell differentiation GO:0045619 regulation of lymphocyte differentiation GO:0045621 positive regulation of lymphocyte differentiation GO:0045861 negative regulation of proteolysis GO:0046328 regulation of JNK cascade GO:0046330 positive regulation of JNK cascade GO:0046822 regulation of nucleocytoplasmic transport GO:0046823 negative regulation of nucleocytoplasmic transport GO:0046824 positive regulation of nucleocytoplasmic transport GO:0050864 regulation of B cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050871 positive regulation of B cell activation GO:0051051 negative regulation of transport GO:0051169 nuclear transport GO:0051170 nuclear import GO:0051220 cytoplasmic sequestering of protein GO:0051222 positive regulation of protein transport GO:0051224 negative regulation of protein transport GO:0051235 maintenance of location GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051346 negative regulation of hydrolase activity GO:0051403 stress-activated MAPK cascade GO:0051651 maintenance of location in cell GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0070227 lymphocyte apoptotic process GO:0070228 regulation of lymphocyte apoptotic process GO:0070229 negative regulation of lymphocyte apoptotic process GO:0070231 T cell apoptotic process GO:0070232 regulation of T cell apoptotic process GO:0070233 negative regulation of T cell apoptotic process GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0070304 positive regulation of stress-activated protein kinase signaling cascade GO:0071356 cellular response to tumor necrosis factor GO:0071887 leukocyte apoptotic process GO:0090316 positive regulation of intracellular protein transport GO:0090317 negative regulation of intracellular protein transport GO:0097191 extrinsic apoptotic signaling pathway GO:0097305 response to alcohol GO:1900180 regulation of protein localization to nucleus GO:1900181 negative regulation of protein localization to nucleus GO:1900182 positive regulation of protein localization to nucleus GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1902532 negative regulation of intracellular signal transduction GO:1902593 single-organism nuclear import GO:1903533 regulation of protein targeting GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:1903828 negative regulation of cellular protein localization GO:1903829 positive regulation of cellular protein localization GO:1904589 regulation of protein import GO:1904590 negative regulation of protein import GO:1904591 positive regulation of protein import GO:1904950 negative regulation of establishment of protein localization GO:1904951 positive regulation of establishment of protein localization GO:2000106 regulation of leukocyte apoptotic process GO:2000107 negative regulation of leukocyte apoptotic process GO:2000116 regulation of cysteine-type endopeptidase activity GO:2000117 negative regulation of cysteine-type endopeptidase activity
Molecular Function	GO:0004857 enzyme inhibitor activity GO:0004866 endopeptidase inhibitor activity GO:0004869 cysteine-type endopeptidase inhibitor activity GO:0005031 tumor necrosis factor-activated receptor activity GO:0005035 death receptor activity GO:0030414 peptidase inhibitor activity GO:0043027 cysteine-type endopeptidase inhibitor activity involved in apoptotic process GO:0043028 cysteine-type endopeptidase regulator activity involved in apoptotic process GO:0061134 peptidase regulator activity GO:0061135 endopeptidase regulator activity
Cellular Component	GO:0009897 external side of plasma membrane GO:0098552 side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-168256: Immune System R-HSA-5668541: TNFR2 non-canonical NF-kB pathway R-HSA-5669034: TNFs bind their physiological receptors

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CD27 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CD27 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27020860	E7+ tumor TC-1	Promote immunity (infiltration)	Combining CD27 agonism with CTLA-4 blockade improved vaccine-induced CTL priming and tumor infiltration, but only combination with PD-1 blockade was effective at eradicating tumors, thereby fully recapitulating the effect of CD4(+) T-cell help on vaccine efficacy.
16751420	Melanoma	Promote immunity (T cell function)	Incubation in vitro with high doses of IL-2 (3,000 IU/ml) or administration of IL-2 in vivo resulted in substantial up-regulation of CD70 expression and the concomitant loss of cell surface CD27 expression on CD8(+) cells. Withdrawal of IL-2 from activated CD8(+) T cells that had been maintained in IL-2 resulted in a reversal of the expression of these two markers, whereas reciprocal changes were seen following treatment of PBMCs with IL-2. The proliferation observed in cells stimulated with IL-2 primarily occurred in a subset of the CD70(+)CD8(+) T cells that up-regulated IL-2 receptor expression but did not occur in CD70(-)CD8(+) T cells. Blocking CD70 resulted in a significant reduction of T cell proliferation induced by high-dose IL-2, indicating that the interaction of CD70 with CD27 played a direct role in T cell activation mediated by IL-2. Finally, studies conducted on tumor-infiltrating lymphocyte (TIL) samples that were administered to melanoma patients indicated that the size of the pool of CD27(+)CD8(+) T cells in bulk TILs was highly associated (p = 0.004) with the ability of these TILs to mediate tumor regression following adoptive transfer.
29661225	melanoma	Promote immunity (T cell function); essential for immunotherapy	There was differential expression of PD-1 by CD27 status, with expression being higher in the B and T cell subsets associated with memory status (CD27+ and CD27-, respectively; p < 0.001).
29198913	Lymphoma	Promote immunity	Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. Only the anti-CD27/CD20 combination provided cures. Detailed mechanistic analysis using single-cell RNA sequencing demonstrated that anti-CD27 stimulated CD8+T and natural killer cells to release myeloid chemo-attractants and interferon gamma, to elicit myeloid infiltration and macrophage activation.
28011863	Hodgkin Lymphoma	Promote immunity	The proliferation of T cells triggered by CD70-expressing B cells was dependent on CD27 and CD3 on T cells. Importantly, CD27-deficient T cells failed to proliferate when stimulated with CD70-expressing B cells. Thus, the CD70-CD27 pathway appears to be a crucial component of EBV-specific T cell immunity and more generally for the immune surveillance of B cells and may be a target for immunotherapy of B cell malignancies.
22232214	Chronic Myelogenous Leukemia, BCR-ABL1 Positive	Inhibit immunity	CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. Binding of CD27 by its ligand, CD70, increased expression of Wnt target genes in LSCs by enhancing nuclear localization of active β-catenin and TRAF2- and NCK-interacting kinase (TNIK). Blocking CD27 signaling in LSCs delayed disease progression and prolonged survival. Furthermore, CD27 was expressed on CML stem/progenitor cells in the bone marrow of CML patients, and CD27 signaling promoted growth of BCR/ABL+ human leukemia cells by activating the Wnt pathway.
22117050	Ovarian Carcinoma; Breast Carcinoma	Promote immunity	CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. After antigen stimulation in vitro, CD27-bearing CAR-T cells also proliferated, up-regulated Bcl-X(L) protein expression, resisted apoptosis, and underwent increased numerical expansion. The greatest impact of CD27 was noted in vivo, where transferred CAR-T cells with CD27 demonstrated heightened persistence after infusion, facilitating improved regression of human cancer in a xenogeneic allograft model.
25100611	melanoma	Promote immunity	Most importantly, cytotoxic T cells induced by caIKK-transfected DCs combined high CD27 expression, indicating a more memory-like phenotype, and a markedly enhanced secondary expandability with a high lytic capacity.

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CD27 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CD27 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.048	0.939
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.315	0.834
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.15	0.902
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.564	0.202
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.33	0.855
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.865	0.715
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.583	0.271
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.922	0.272
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.228	0.799
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	2.76	0.09
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.027	0.413
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.065	0.814

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CD27 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD27. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD27. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD27. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD27. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CD27 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CD27 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CD27
Name	CD27 molecule
Aliases	S152; TNFRSF7; tumor necrosis factor receptor superfamily, member 7; S152. LPFS2; T14; CD27L receptor; T cel ......
Chromosomal Location	12p13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CD27 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CD27